SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19Plain-Language Summary
Rationale & Objective: A number of serologic tests for immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now commercially available, including multiple lateral flow immunoassays (LFIAs), which have the advantage of being inexpensive and easy to u...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Kidney Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590059520302533 |
id |
doaj-b0dab4c18d1c4db1b9d7c401fca635b3 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maria Prendecki Candice Clarke Tom McKinnon Liz Lightstone Matthew C. Pickering David C. Thomas Stephen P. McAdoo Michelle Willicombe |
spellingShingle |
Maria Prendecki Candice Clarke Tom McKinnon Liz Lightstone Matthew C. Pickering David C. Thomas Stephen P. McAdoo Michelle Willicombe SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19Plain-Language Summary Kidney Medicine SARS-CoV-2 antibodies COVID-19 lateral flow immunoassays (LFIAs) hemodialysis transplant |
author_facet |
Maria Prendecki Candice Clarke Tom McKinnon Liz Lightstone Matthew C. Pickering David C. Thomas Stephen P. McAdoo Michelle Willicombe |
author_sort |
Maria Prendecki |
title |
SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19Plain-Language Summary |
title_short |
SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19Plain-Language Summary |
title_full |
SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19Plain-Language Summary |
title_fullStr |
SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19Plain-Language Summary |
title_full_unstemmed |
SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19Plain-Language Summary |
title_sort |
sars-cov-2 antibody point-of-care testing in dialysis and kidney transplant patients with covid-19plain-language summary |
publisher |
Elsevier |
series |
Kidney Medicine |
issn |
2590-0595 |
publishDate |
2021-01-01 |
description |
Rationale & Objective: A number of serologic tests for immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now commercially available, including multiple lateral flow immunoassays (LFIAs), which have the advantage of being inexpensive and easy to use, without the reliance on laboratory facilities. However, data on the development of humoral immunity to SARS-CoV-2 in patients with kidney disease is limited, and the utility of an LFIA to test for antibodies in these patients has not been assessed. Study Design: Observational study. Setting & Participants: 60 patients (40 hemodialysis and 20 kidney transplant recipients) with SARS-CoV-2 infection confirmed by viral reverse transcriptase–polymerase chain reaction (RT-PCR) testing and 88 historic negative-control samples (collected before September 2019). Test: A commercially available LFIA to test for SARS-CoV-2 IgG in patients with infection confirmed by viral RT-PCR testing. Outcomes: Sensitivity and specificity of the LFIA to detect SARS-CoV-2 IgG in dialysis patients and transplant recipients. Results: 56/58 (96.6%) patients (38/39 hemodialysis and 18/19 transplant recipients) tested positive for SARS-CoV-2 IgG. 5/7 (71.4%) patients who were negative on preliminary testing had detectable IgG when retested more than 21 days postdiagnosis. Median times to first and second tests after diagnosis were 17 (interquartile range, 15-20) and 35 (interquartile range, 30-39) days, respectively. Calculation of test characteristics gave sensitivity of 96.6% (95% CI, 88.3%-99.4%) and specificity of 97.7% (95% CI, 92.0-99.6%). Limitations: Possible exposure to other beta-coronaviruses that may cross-react with the antigen used in the LFIA cannot be excluded. Conclusions: Symptomatic dialysis patients and transplant recipients commonly develop an immune response against SARS-CoV-2 infection that can be detected using an LFIA. Used diligently, an LFIA could be used to help screen the dialysis populations or confirm exposure on a patient level, especially in facilities in which laboratory resources are limited. |
topic |
SARS-CoV-2 antibodies COVID-19 lateral flow immunoassays (LFIAs) hemodialysis transplant |
url |
http://www.sciencedirect.com/science/article/pii/S2590059520302533 |
work_keys_str_mv |
AT mariaprendecki sarscov2antibodypointofcaretestingindialysisandkidneytransplantpatientswithcovid19plainlanguagesummary AT candiceclarke sarscov2antibodypointofcaretestingindialysisandkidneytransplantpatientswithcovid19plainlanguagesummary AT tommckinnon sarscov2antibodypointofcaretestingindialysisandkidneytransplantpatientswithcovid19plainlanguagesummary AT lizlightstone sarscov2antibodypointofcaretestingindialysisandkidneytransplantpatientswithcovid19plainlanguagesummary AT matthewcpickering sarscov2antibodypointofcaretestingindialysisandkidneytransplantpatientswithcovid19plainlanguagesummary AT davidcthomas sarscov2antibodypointofcaretestingindialysisandkidneytransplantpatientswithcovid19plainlanguagesummary AT stephenpmcadoo sarscov2antibodypointofcaretestingindialysisandkidneytransplantpatientswithcovid19plainlanguagesummary AT michellewillicombe sarscov2antibodypointofcaretestingindialysisandkidneytransplantpatientswithcovid19plainlanguagesummary |
_version_ |
1724283509096316928 |
spelling |
doaj-b0dab4c18d1c4db1b9d7c401fca635b32021-02-05T15:32:20ZengElsevierKidney Medicine2590-05952021-01-01315459.e1SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19Plain-Language SummaryMaria Prendecki0Candice Clarke1Tom McKinnon2Liz Lightstone3Matthew C. Pickering4David C. Thomas5Stephen P. McAdoo6Michelle Willicombe7Centre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United Kingdom; Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United KingdomCentre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United Kingdom; Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United KingdomCentre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United KingdomCentre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United Kingdom; Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United KingdomCentre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United KingdomCentre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United Kingdom; Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United KingdomCentre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United Kingdom; Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United KingdomCentre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United Kingdom; Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom; Address for Correspondence: Michelle Willicombe, MD, Centre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, W12 0NN.Rationale & Objective: A number of serologic tests for immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now commercially available, including multiple lateral flow immunoassays (LFIAs), which have the advantage of being inexpensive and easy to use, without the reliance on laboratory facilities. However, data on the development of humoral immunity to SARS-CoV-2 in patients with kidney disease is limited, and the utility of an LFIA to test for antibodies in these patients has not been assessed. Study Design: Observational study. Setting & Participants: 60 patients (40 hemodialysis and 20 kidney transplant recipients) with SARS-CoV-2 infection confirmed by viral reverse transcriptase–polymerase chain reaction (RT-PCR) testing and 88 historic negative-control samples (collected before September 2019). Test: A commercially available LFIA to test for SARS-CoV-2 IgG in patients with infection confirmed by viral RT-PCR testing. Outcomes: Sensitivity and specificity of the LFIA to detect SARS-CoV-2 IgG in dialysis patients and transplant recipients. Results: 56/58 (96.6%) patients (38/39 hemodialysis and 18/19 transplant recipients) tested positive for SARS-CoV-2 IgG. 5/7 (71.4%) patients who were negative on preliminary testing had detectable IgG when retested more than 21 days postdiagnosis. Median times to first and second tests after diagnosis were 17 (interquartile range, 15-20) and 35 (interquartile range, 30-39) days, respectively. Calculation of test characteristics gave sensitivity of 96.6% (95% CI, 88.3%-99.4%) and specificity of 97.7% (95% CI, 92.0-99.6%). Limitations: Possible exposure to other beta-coronaviruses that may cross-react with the antigen used in the LFIA cannot be excluded. Conclusions: Symptomatic dialysis patients and transplant recipients commonly develop an immune response against SARS-CoV-2 infection that can be detected using an LFIA. Used diligently, an LFIA could be used to help screen the dialysis populations or confirm exposure on a patient level, especially in facilities in which laboratory resources are limited.http://www.sciencedirect.com/science/article/pii/S2590059520302533SARS-CoV-2 antibodiesCOVID-19lateral flow immunoassays (LFIAs)hemodialysistransplant |